Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:7/29/2008

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide a corporate overview, including a discussion of the clinical development program and regulatory strategy for picoplatin, the Company's lead product candidate.

* Oppenheimer & Co. Inc.'s Small & Mid Cap Clinical & Regulatory Conference on Monday, August 4, at 8:40 a.m. Eastern Time at the Oppenheimer office in New York. Mr. Martell will discuss Poniard's clinical development programs and regulatory strategy, and then participate in a subsequent panel discussion, entitled "Designing A Pivotal Program with an Eye Towards Approval." During this discussion, which begins at 9:55 a.m., Mr. Martell will discuss the regulatory path to approval for picoplatin.

* BMO Capital Markets' 2008 Focus on Healthcare Conference on Tuesday, August 5, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York.

A live audio webcast of each Poniard presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
2. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
3. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Announces Upcoming Conference Participation
5. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
6. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
10. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
11. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... The ... Denver, Colorado October 28 and 29, 2017, to promote AMA’s programs, member services, ... participation in different hobbies, including but not limited to model aviation and other ...
(Date:9/21/2017)... ... ... Greg Leyer, Chief Scientific Officer of UAS Labs, will be presenting at SupplySide West ... Probiotics Resource Center, Mandalay Bay Expo Hall. , “I am very pleased to ... data in areas outside the gut including heart health, Vitamin D status, upper respiratory ...
(Date:9/21/2017)... ... September 21, 2017 , ... Executives and subject ... most progressive pharma and biotech organizations to do more clinical trials will share ... events in Q4. , DrugDev will demonstrate DrugDev Spark™, the world’s first unified ...
(Date:9/21/2017)... DIEGO, CALIF. (PRWEB) , ... September 21, 2017 , ... ... earlier this month. The organization, a worldwide society of professional women with high ... venue to hold its annual dinner. , Twelve members began with an ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
Breaking Biology News(10 mins):